Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of XS003 (Nilotinib) vs Tasigna in Healthy Adults
NCT07138378Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of XS003 in chronic myeloid leukemia (CML) (4 arms), sponsored by Xspray Pharma. Primary endpoints: Peak Plasma Concentration and Area Under the Plasma Concentration versus Time Curve. Started Nov 2024; status: completed.
02
Drugs
XS003
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07138378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138378.